Article Link: FDA Approves Merck’s Keytruda (pembrolizumab) for Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma ...
FDA Expands Approved Use of Kalydeco to Treat Additional Mutations of Cystic Fibrosis
Article Link: FDA Expands Approved Use of Kalydeco to Treat Additional Mutations of Cystic Fibrosis Source: FDA New Drug Ap...
FDA Approves Merck’s Keytruda (pembrolizumab) as First-Line Combination Therapy for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC), Irrespective of PD-L1 Expression
Article Link: FDA Approves Merck’s Keytruda (pembrolizumab) as First-Line Combination Therapy for Patients with Metastatic Nonsquamous Non-Small Cell ...
FDA Grants Accelerated Approval to Bavencio (avelumab) for Urothelial Carcinoma
Article Link: FDA Grants Accelerated Approval to Bavencio (avelumab) for Urothelial Carcinoma Source: FDA New Drug Approval...
FDA Approves Radicava (edaravone) to Treat Amyotrophic Lateral Sclerosis (ALS)
Article Link: FDA Approves Radicava (edaravone) to Treat Amyotrophic Lateral Sclerosis (ALS) Source: FDA New Drug Approvals
AstraZeneca’s Imfinzi (durvalumab) Receives FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer
Article Link: AstraZeneca’s Imfinzi (durvalumab) Receives FDA Accelerated Approval for Previously Treated Patients with Advanced Bladder Cancer ...
Takeda Announces FDA Accelerated Approval of Alunbrig (brigatinib)
Article Link: Takeda Announces FDA Accelerated Approval of Alunbrig (brigatinib) Source: FDA New Drug Approvals
FDA Approves Tymlos (abaloparatide) for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
Article Link: FDA Approves Tymlos (abaloparatide) for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture &...
FDA Approves Rydapt (midostaurin) for FLT3-Mutated Acute Myeloid Leukemia and Systemic Mastocytosis
Article Link: FDA Approves Rydapt (midostaurin) for FLT3-Mutated Acute Myeloid Leukemia and Systemic Mastocytosis Source: F...
FDA Approves Brineura (cerliponase alfa) for CLN2 Disease, a Form of Batten Disease
Article Link: FDA Approves Brineura (cerliponase alfa) for CLN2 Disease, a Form of Batten Disease Source: FDA New Drug Appr...
